Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

被引：0

作者：

Hochhaus, Andreas ^{[1
]}

Cortes, Jorge E. ^{[2
]}

Kim, Dong-Wook ^{[3
]}

Pinilla-Ibarz, Javier ^{[4
]}

le Coutre, Philipp D. ^{[5
]}

Paquette, Ronald ^{[6
]}

Chuah, Charles ^{[7
]}

Nicolini, Franck. E. ^{[8
]}

Apperley, Jane F. ^{[9
]}

Khoury, H. Jean ^{[10
]}

Talpaz, Moshe ^{[11
]}

DeAngelo, Daniel J. ^{[12
]}

Abruzzese, Elisabetta ^{[13
]}

Rea, Delphine ^{[14
]}

Baccarani, Michele ^{[15
]}

Muller, Martin C. ^{[16
]}

Gambacorti-Passerini, Carlo ^{[17
]}

Lustgarten, Stephanie ^{[18
]}

Conlan, Maureen ^{[18
]}

Rivera, Victor M. ^{[18
]}

Guilhot, Francois ^{[19
]}

Deininger, Mochael W. ^{[20
]}

Hughes, Timothy P. ^{[21
,22
]}

Shah, Neil P. ^{[23
]}

Kantarjian, Hagop M. ^{[24
]}

机构：

[1] Jena Univ Hosp, Jena, Germany

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[3] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea

[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA

[5] Charite, D-13353 Berlin, Germany

[6] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA

[7] Singapore Gen Hosp, Dept Hematol, Singapore, Singapore

[8] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France

[9] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[12] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[13] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy

[14] Hop St Louis, Dept Hematol, Paris, France

[15] Univ Bologna, Inst Hematol, Bologna, Italy

[16] Univ Med Mannheim, Mannheim, Germany

[17] Univ Milano Bicocca, Azienda Osped San Gerardo, Monza, Italy

[18] ARIAD Pharmaceut Inc, Cambridge, MA USA

[19] CHU Poitiers, INSERM, CIC 1402, Poitiers, France

[20] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[21] SA Pathol, Adelaide, SA, Australia

[22] Univ Adelaide, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[23] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[24] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Conlan, Maureen
Guilhot, Francois
Deininger, Mochael W.
Hochhaus, Andreas
Hughes, Timothy P.
Kantarjian, Hagop M.
Shah, Neil P.
BLOOD, 2015, 126 (23)
[2] Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial
Kim, Dong-Wook
Cortes, Jorge E.
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)
[3] Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study
Hochhaus, Andreas
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck Emmanuel
Talpaz, Moshe
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Castagnetti, Fausto
Milojkovic, Dragana
Lustgarten, Stephanie
Rivera, Victor M.
Neumann, Frank
Guilhot, Francois
Deininger, Michael W.
Hughes, Timothy P.
Shah, Neil P.
Kantarjian, Hagop M.
BLOOD, 2017, 130
[4] Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Kantarjian, Hagop M.
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
BLOOD, 2013, 122 (21)
[5] Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study
Etienne, Gabriel
Rea, Delphine
Coiteux, Valerie
Guerci-Bresle, Agnes
Huguet, Francoise
Legros, Laurence
Rousselot, Philippe
Nicolini, Franck-Emmanuel
LEUKEMIA RESEARCH, 2021, 104
[6] Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Hochhaus, Andreas
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Deininger, Michael W.
Hughes, Timothy P.
Goldman, John M.
Shah, Neil P.
Kantarjian, Hagop M.
Guilhot, Francois
BLOOD, 2013, 122 (21)
[7] Long-Term Follow-up of Ponatinib Efficacy and Safety in the Phase 2 PACE Trial
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Le Coutre, Philipp
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane F.
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Rivera, Victor M.
Clackson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Kantarjian, Hagop M.
BLOOD, 2014, 124 (21)
[8] Five-year results of the ponatinib phase II PACE trial in heavily pretreated CP-CML patients (pts).
Kantarjian, Hagop M.
Pinilla-Ibarz, Javier
Le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, Hanna Jean
Talpaz, Moshe
Baccarani, Michele
Lustgarten, Stephanie
Santillana, Sergio
Guilhot, Francois
Deininger, Michael W. N.
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
Talpaz, M.
Cortes, J. E.
Kantarjian, H. M.
Shah, N. P.
Bixby, D. L.
Flinn, I. W.
O'Hare, T. J.
Hu, S.
Rivera, V. M.
Clackson, T.
Conlan, M. G.
Haluska, F. G.
Druker, B. J.
Deininger, M. W.
Mauro, M. J.
HAEMATOLOGICA, 2015, 100 : 65 - 66
[10] Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
Talpaz, Moshe
Cortes, Jorge E.
Kantarjian, Hagop M.
Shah, Neil P.
Bixby, Dale L.
Flinn, Ian
O'Hare, Thomas J.
Hu, Simin
Rivera, Victor M.
Clackson, Timothy Piers
Conlan, Maureen G.
Haluska, Frank G.
Druker, Brian J.
Deininger, Michael W. N.
Mauro, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →